1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel

Competitor Analysis: TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel

The present Competitive Intelligence report about TNF Antibodies 2015– Biosimilars and Biosuperiors of Humira, Remicade and Enbrel provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The five branded anti-TNF antibodies Humira, Remicade, Enbrel, Simponi and Cimzia together achieved global sales of US$ 34.4 bln (+12.9%) in the year 2014. While the first biosimilars of Humira, Remicade and Enbrel are already marketed in less regulated countries such as India and China, it is only in February of 2015 that a biosimilar TNF antibody has been launched in the European Union. The Marketing Authorization Applications of further two biosimilar TNF antibodies have been just been submitted to the European Medicines Agency and the clinical pipeline of is rather full.

The report includes a compilation of currently active R&D projects of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents

Competitor Analysis: TNF Antibodies 2015- Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
Competitor Analysis: TNF Antibodies 2015- Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
Table of Contents:
1. TNF Antibodies 2015 - Biosimilars and Biosuperiors of Humira, Remicade and Enbrel
Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
-           Humira Sales and Pipeline
-           Remicade Sales and Pipeline
-           Enbrel Sales and Pipeline
-           Simponi Sales and Pipeline
-           Cimzia Sales and Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
-           Humira Biosimilar Antibody Pipeline
-           Remicade Biosimilar Antibody Pipeline
-           Enbrel Biosimilar Antibody Pipeline
-           Cimzia Biosimilar Antibody Pipeline
2.  Corporate TNF Antibody Biosimilar and Biosuperior Pipelines

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global and Chinese Biosimilar Monoclonal Antibodies Industry, 2016 Market Research Report

Global and Chinese Biosimilar Monoclonal Antibodies Industry, 2016 Market Research Report

  • $ 2800
  • Industry report
  • December 2016
  • by Prof Research

The ’Global and Chinese Biosimilar Monoclonal Antibodies Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global Biosimilar Monoclonal Antibodies ...

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017

  • $ 1995
  • Industry report
  • February 2017
  • by Currentpartnering

Summary The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture partnering ...

Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016

Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016

  • $ 1450
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s, “Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016” discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars ...


Download Unlimited Documents from Trusted Public Sources

Global Insulin Market

  • February 2017
    115 pages
  • Insulin  

    Obesity  

    Blood Disease  

  • World  

    United States  

    Asia  

View report >

Therapy Market in the US

  • January 2017
    27 pages
  • United States  

View report >

Therapy Market - Forecast

  • January 2017
    4 pages
  • Therapy  

View report >

Related Market Segments :

Biosimilar

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.